Your browser doesn't support javascript.
loading
Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells.
Kim, Lee-Han; Shin, Ji-Ae; Jang, Boonsil; Yang, In-Hyoung; Won, Dong-Hoon; Jeong, Joseph H; Chung, Tae-Ho; Cho, Nam-Pyo; Cho, Sung-Dae.
Afiliación
  • Kim LH; Department of Oral Pathology, School of Dentistry, Institute of Biodegradable material, Institute of Oral Bioscience, Chonbuk National University, Jeonju 54986, Republic of Korea.
  • Shin JA; Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Alkek Building for Biomedical Research, Houston, TX, 77030, USA.
  • Jang B; Department of Oral Pathology, School of Dentistry, Institute of Biodegradable material, Institute of Oral Bioscience, Chonbuk National University, Jeonju 54986, Republic of Korea.
  • Yang IH; Department of Oral Pathology, School of Dentistry, Institute of Biodegradable material, Institute of Oral Bioscience, Chonbuk National University, Jeonju 54986, Republic of Korea.
  • Won DH; Department of Oral Pathology, School of Dentistry, Institute of Biodegradable material, Institute of Oral Bioscience, Chonbuk National University, Jeonju 54986, Republic of Korea.
  • Jeong JH; Department of Urology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
  • Chung TH; Department of Animal Resources Science, Joongbu University, Chungnam, 32713, Republic of Korea.
  • Cho NP; Department of Oral Pathology, School of Dentistry, Institute of Biodegradable material, Institute of Oral Bioscience, Chonbuk National University, Jeonju 54986, Republic of Korea.
  • Cho SD; Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul 03080, Republic of Korea. Electronic address: efiwdsc@gmail.com.
Arch Oral Biol ; 73: 1-6, 2017 Jan.
Article en En | MEDLINE | ID: mdl-27632413
OBJECTIVE: The mimetic BH3 ABT-737, a potent inhibitor of anti-apoptotic Bcl-2 family proteins, has potential as anti-cancer drug in many cancers. Recently, patients treated with ABT-737 have developed drug tolerance during cancer therapy. Therefore, we examined whether ABT-737 is effective in killing MC-3 and HSC-3 human oral cancer cells either alone or in combination with the oncogenic kinase inhibitor, sorafenib. DESIGN: The potentiating activities of sorafenib in ABT-737-induced apoptosis were determined using trypan blue exclusion assay, DAPI staining, cell viability assay and Western blot analysis. RESULTS: Combined use of ABT-737 and sorafenib synergistically suppressed cell viability and induced apoptosis compared with either compound individually. The combination of ABT-737 and sorafenib altered only Bax and Bak proteins and their activations, resulting in mitochondrial translocation of Bax from the cytosol. Additionally, combination treatment-mediated apoptosis may be correlated with ERK and STAT3 pathways. CONCLUSIONS: These results suggest that sorafenib may effectively overcome ABT-737 resistance to apoptotic cell death, which can be a new potential chemotherapeutic strategy against human oral cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Sulfonamidas / Compuestos de Bifenilo / Apoptosis / Niacinamida / Antineoplásicos / Nitrofenoles Límite: Humans Idioma: En Revista: Arch Oral Biol Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Sulfonamidas / Compuestos de Bifenilo / Apoptosis / Niacinamida / Antineoplásicos / Nitrofenoles Límite: Humans Idioma: En Revista: Arch Oral Biol Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido